AstraZeneca signs five-year licensing deal for RNA therapeutics
AstraZeneca has signed a five-year licensing deal with Moderna Therapeutics, a US biotechnology company specialising in drugs using RNA therapeutics.
Bayer sues Glenmark over generic Finacea
Pharmaceutical companies Bayer, Intendis and Intraserv have filed a patent infringement lawsuit against Glenmark after it applied to market a generic version of rosacea treatment Finacea.
Mylan signs generic truce with Shionogi and Andrx
Generic drug maker Mylan has struck a deal with pharma companies Shionogi and Andrx to resolve a patent dispute over their diabetes drug Fortamet.
Janssen sues Hetero over generic HIV treatment
Janssen Products, a subsidiary of Johnson & Johnson, has sued Indian pharmaceutical company Hetero Drugs for applying to market a generic version of its HIV treatment Prezista.
1st Annual Life Sciences Law Forum: confusion over SPCs
Recent CJEU judgements on the interpretation of SPC regulations are not clear and have left judges frustrated, said Huw Evans, partner at Norton Rose LLP, at the 1st Annual Life Sciences Law Forum in London.
1st Annual Life Sciences Law Forum: what do we know about the Unitary Patent?
Day two of the 1st Annual Life Sciences Forum in London saw panellists discuss the European Unitary Patent and the Unified Patent Court.
Australian Myriad ruling to face appeal
Law firm Maurice Blackburn revealed on Monday that it will appeal against an Australian court decision that backed Myriad Genetics’ ownership of a human gene mutation linked to breast cancer.
India rejects Bayer plea over compulsory licence
India’s patent authorities have dealt a blow to German pharma company Bayer by refusing to overturn an order forcing the company to license one of its patented drugs.
ViiV Healthcare joins patent pool for cheaper AIDS drugs
ViiV Healthcare, a public health joint venture between GlaxoSmithKline, Shionogi and Pfizer, has signed up to the Medicines Patent Pool (MPP) to provide greater access to affordable AIDS treatments in developing countries.
UK patent change paves way for pharma innovation
The UK government announced a change to the Patent Act on Tuesday that will allow parties to run drug trials without infringing other parties’ patents.
